Spyre Therapeutics Inc. experienced a notable increase in its stock price, reflecting positive investor sentiment.
Spyre Therapeutics Inc. (NASDAQ:SYRE) went up yesterday by 5.09%, closing at CA$89.03. This surge comes amid a backdrop of positive developments in the company's clinical trials and strategic initiatives.
Advertisement
Spyre Therapeutics Inc.
SYRE.US
SYRE.US
Spyre Therapeutics Inc.
WealthAwesomeMarket cap
$7.85B
52W high
$110.17
52W low
$15.86
1W change
+0.98%
Beta
3.00
Analyst Price Targets
Based on 11 analysts covering SYRE · as of Sep 17, 2026
Wall Street analysts forecast SYRE stock price to rise 34.9% over the next 12 months.
Consensus
Strong Buy4.82 / 5.00
Avg. Target
C$120.08
+34.9% Upside
Current Price
C$89.03
Last close
Analyst Breakdown (11 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on SYRE's historical volatility
30-Day Vol
50.6%
Annualized
90-Day Vol
62.2%
Annualized
Trend (90d)
-23.8%
Annualized drift
90d Mean
C$81.76
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$86.54 | C$72.68 – C$103.04 |
| 60 trading days | C$84.12 | C$65.72 – C$107.67 |
| 90 trading days | C$81.76 | C$60.43 – C$110.63 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are responding favorably to Spyre's recent trial results and the company's ongoing commitment to innovation in therapeutics.
5.09% Surge in Stock Price
Spyre's stock price increase reflects growing optimism about the company's future prospects following recent trial successes.
Bull case
The successful results from the SKYLINE trial for SPY003 show strong potential for the drug, which could boost market confidence and attract more investment in Spyre.
Bear case
Even with the positive trial results, the company still needs to establish a consistent revenue stream, which could pose risks for investors in the long run.
Advertisement
Positive Trial Results Boost Confidence
The recent announcement regarding the SKYLINE trial results for SPY003 has significantly contributed to the surge in Spyre's stock price. The trial showed a notable reduction in the Robart’s Histopathology Index score, boosting investor confidence in the drug's effectiveness.
Market Reaction and Future Outlook
The market's positive reaction to Spyre's stock performance highlights the potential for future growth as the company advances its pipeline. Investors are closely watching for more developments, especially in clinical trials that could lead to new therapeutic options.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
